<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00134667</url>
  </required_header>
  <id_info>
    <org_study_id>EOP1012</org_study_id>
    <nct_id>NCT00134667</nct_id>
  </id_info>
  <brief_title>Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)</brief_title>
  <official_title>A Phase IIIb/IV Randomized, Double-Masked, Active Controlled, Dose-Ranging, Multi-Center Comparative Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 6 Weeks for 102 Weeks, to Pegaptanib Sodium Plus Photodynamic Therapy (PDT) With Visudyne, in Patients With Exudative Age-Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyetech Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eyetech Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of the trial is to compare whether Macugen (pegaptanib sodium) in combination
      with PDT with Visudyne (verteporfin) is safe and effective in slowing down the leakage of
      fluid within the eye and thereby stabilizing or improving vision when compared to Macugen
      alone. Patients must be recently diagnosed with predominantly classic wet AMD and must be
      eligible for PDT.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>March 2005</start_date>
  <completion_date>October 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>360</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Photodynamic Therapy (PDT) with Visudyne (verteporfin)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macugen (pegaptanib sodium)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of either gender; aged 50 years or greater.

          -  Subfoveal choroidal neovascularization (CNV) due to AMD with predominantly classic
             lesion composition

          -  Best corrected visual acuity in the study eye between 20/40 and 20/200

        Exclusion Criteria:

          -  Any prior PDT with Visudyne to the study eye

          -  Any previous AMD thermal laser therapy to the study eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Retina Centers, P.C., Northwest Location</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704-5614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2005</study_first_submitted>
  <study_first_submitted_qc>August 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2005</study_first_posted>
  <last_update_submitted>January 12, 2007</last_update_submitted>
  <last_update_submitted_qc>January 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2007</last_update_posted>
  <keyword>AMD</keyword>
  <keyword>Age-Related Macular Degeneration</keyword>
  <keyword>Macular Degeneration</keyword>
  <keyword>Macugen</keyword>
  <keyword>Photodynamic Therapy</keyword>
  <keyword>PDT</keyword>
  <keyword>Visudyne</keyword>
  <keyword>pegaptanib sodium</keyword>
  <keyword>verteporfin</keyword>
  <keyword>Predominantly Classic</keyword>
  <keyword>Age-Related Macular Degeneration (AMD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

